Clinical trials: Second-Line
Metastatic Renal Cell Carcinoma
Efficacy Study of Sunitinib and Everolimus (Rotational vs Sequential Arm) in Pats. With m Clear Cell Renal Cancer
The objective of this study is to assess the progression-free survival, of patients who receive rotations of sunitinib and everolimus versus patients who receive sunitinib as a first line treatment followed by everolimus when…
- Trial name
- SUNRISES (NCT01784978)
- Testing
- Sunitinib, Everolimus
- Where
- 10 sites in France, Greece and 1 more
- Volunteers
- 41 people
- Sponsor
- Associació per a la Recerca Oncologica, Spain
Colorectal Cancer Metastatic
A Study of Aflibercept in Combination With FOLFIRI in Patients With Second-Line Metastatic Colorectal Cancer in Japan
Primary Objective: To assess efficacy aflibercept + 5-fluorouracil (5-FU)/levofolinate/irinotecan (FOLFIRI) by objective response rate (ORR).
- Trial name
- NCT01882868
- Testing
- Aflibercept, Levofolinate, Irinotecan
- Where
- 19 sites in Japan
- Volunteers
- 62 people
- Sponsor
- Sanofi
Biliary Tract Adenocarcinoma
Fruquintinib as Second-line Treatment for Advanced/Metastatic Biliary Tract Adenocarcinoma
The prospective, multicenter, single-arm design study is to evaluate the efficacy and safety of fruquintinib for patients with advanced or metastatic biliary tract adenocarcinoma who failed first-line chemotherapy with…
- Trial name
- FSTAMBTA (NCT04156958)
- Testing
- Fruquintinib
- Where
- 7 sites in China
- Volunteers
- 33 people
- Sponsor
- Sichuan University
Lung Cancer Metastatic
SBRT Combination With rhGM-CSF and Tα1 for Stage IV NSCLC Patients Who Failed in Second-line Chemotherapy
The purpose of this study is to determine whether stereotactic body radiotherapy (SBRT) combined with recombined human granulocyte-macrophage colony stimulating factor(rhGM-CSF) and Thymosin Alpha 1 is safe, effective in the…
- Trial name
- NCT02976740
- Testing
- SBRT, Immunological Agent, Immunological Factors
- Where
- China
- Volunteers
- 48 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Adenocarcinoma of the Stomach
EGFR-targeted Therapy for Gastric Cancer
Based on targeted NGS panel results, metastatic gastric cancer patients with gene amplifications will receive either anti-EGFR antibody (GC-1118) in combination with weekly paclitaxel as a second-line therapy.
- Trial name
- NCT04077255
- Testing
- Anti-EGFR antibody in combination with weekly paclitaxel
- Where
- South Korea
- Volunteers
- 19 people
- Sponsor
- National Cancer Center, Korea
Colon Cancer, Rectal Cancer
A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)
This is an open-label multicenter, single-arm Phase II study of Fruquintinib in combination with FOLFIRI (leucovorin calcium (folinic acid), fluorouracil, and irinotecan) in participants with metastatic colorectal cancer (mCRC).
- Conditions
- Colon Cancer, Rectal Cancer, Colorectal Cancer, Colorectal Cancer (CRC)
- Trial name
- FRUITFUL (NCT07011576)
- Testing
- fruquintinib, FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)
- Where
- 14 sites in United States
- Volunteers
- 60 people
- Sponsor
- SCRI Development Innovations, LLC
First-line Non-small-cell Lung Cancer, First-line Urothelial Carcinoma
Clinical Trial of TJ271 Injection Combined With Pembrolizumab in the Treatment of Advanced Solid Tumors
A Multi-center, Open-label Phase II Clinical Trial of TJ271 Injection in Combination with Pembrolizumab in Chinese Patients with Advanced Solid Tumors to evaluate the anti-tumor efficacy, safety, pharmacokinetics and…
- Conditions
- First-line Non-small-cell Lung Cancer, First-line Urothelial Carcinoma, Second-line Urothelial Carcinoma, Second-line Melanoma
- Trial name
- NCT05338580
- Testing
- TJ271 Injection in Combination with Pembrolizumab
- Where
- China
- Sponsor
- TJ Biopharma Co., Ltd.
Helicobacter Pylori Treatment Failure
High Dose Amoxicillin Versus Tetracycline as Second-line Treatment of Resistant Helicobacter Pylori Infection
No trial has examined the the efficacy of high dose amoxicillin based quadruple therapy as second-line treatment for Helicobacter pylori infection.
- Trial name
- NCT02175927
- Testing
- Lansoprazole, Bismuth Potassium Citrate, Metronidazole
- Where
- China
- Volunteers
- 312 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Colorectal Cancer
Cetuximab and Bevacizumab as First-Line Therapy Followed By Combination Chemotherapy and Bevacizumab With or Without Cetuximab as Second-Line Therapy in Treating Patients With Stage IV Colorectal Cancer
RATIONALE: Monoclonal antibodies, such as cetuximab and bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00571740
- Testing
- bevacizumab, cetuximab, fluorouracil
- Sponsor
- Alliance for Clinical Trials in Oncology
Multiple Myeloma in Relapse, Refractory Multiple Myeloma
Ixazomib-pomalidomide-dexamethasone as Second or Third-line Combination Treatment for Patients With Relapsed and Refractory Multiple Myeloma Previously Treated With Daratumumab, Lenalidomide and Bortezomib
Adult patients with a confirmed diagnosis of symptomatic and relapsed and/or refractory MM, after receiving bortezomib, lenalidomide and daratumumab during first and second lines, will be eligible to be enrolled in this study.
- Trial name
- IPoD-790 (NCT04790474)
- Testing
- ixazomib-pomalidomide-dexamethasone
- Where
- 7 sites in Israel
- Volunteers
- 61 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Hepatocellular Carcinoma
Study of TAC-101 as Second Line Treatment in Patients With Advanced Hepatocellular Carcinoma Who Received Sorafenib as First Line Therapy
The purpose of this study is to determine whether TAC-101 as a second line therapy for participants who received Sorafenib as first line therapy is effective in slowing tumor activity in patients with advanced hepatocellular…
- Trial name
- NCT00687596
- Testing
- TAC-101
- Where
- Italy
- Volunteers
- 52 people
- Sponsor
- Taiho Oncology, Inc.
Colorectal Cancer
A Safety Study of Pentamidine in Patients With Metastatic Colon Cancer Undergoing Standard Chemotherapy as Second-line and/or Third-line Treatment
The purpose of this study is to investigate the safety and possible efficacy of the use of pentamidine in the treatment of colon cancer metastasis in subjects receiving standard therapy.
- Trial name
- NCT00809796
- Testing
- pentamidine
- Where
- Canada
- Volunteers
- 15 people
- Sponsor
- Oncozyme Pharma Inc.
Multiple Myeloma
A Study to Evaluate the Subcutaneous Belantamab (BCMAb) Formulation Versus Intravenous Belantamab in Participants With Multiple Myeloma While Treated With Standard of Care
This study aims to compare how belantamab behaves in the body when given as an injection under the skin (SC) versus into a vein (IV) in participants with multiple myeloma who are receiving standard of care treatment, to enable…
- Trial name
- DynaMMic-2 (NCT07742527)
- Testing
- Belantamab SC, Belantamab IV, Recombinant Human Hyaluronidase PH20 (rHuPH20)
- Volunteers
- 22 people
- Sponsor
- GlaxoSmithKline
Colorectal Cancer
Real World Study of Regorafenib Versus Fruquintinib in Colorectal Cancer
This is an observational, ambispective cohort study. The aim is to compare the efficacy and safety of regorafenib versus fruquintinib conducted in China.
- Trial name
- NCT04431791
- Testing
- Regorafenib, Fruquintinib
- Where
- China
- Volunteers
- 268 people
- Sponsor
- Peking University
Obstructive Sleep Apnea
Prospective Cohort Study of Patients Intolerant to High Pressure Under Continuous Positive Airway Pressure Treated With Bilevel Positive Airway Pressure as Second-line Therapy.
Prospective observational study of obstructive Sleep Apnea patients treated with Bilevel Positive Airway Pressure: AirCurve 10 VAutoTM
- Trial name
- PoP IN VAuto (NCT02930460)
- Where
- 8 sites in France
- Volunteers
- 30 people
- Sponsor
- ResMed
Malignant Mesothelioma
A Clinical Study With Tremelimumab as Monotherapy in Malignant Mesothelioma
The study is designed to define the immunologic and clinical activity of Tremelimumab in patients with advanced mesothelioma.
- Trial name
- NCT01649024
- Testing
- Tremelimumab
- Where
- Italy
- Volunteers
- 29 people
- Sponsor
- Azienda Ospedaliera Universitaria Senese
Melanoma
Multi-Centre, Retrospective, Open Label Study, to Validate ML-PrediCare by Patients With Melanoma Under 1st and 2nd Lines of Immunotherapy
This is a retrospective, open label study to establish and validate a prediction technology for advanced melanoma patients under the 1st, 2nd and later treatment lines, with the immunotherapeutic drugs Ipilimumab, Pembrolizumab…
- Trial name
- NCT02581228
- Testing
- ML-PrediCare
- Where
- Israel
- Volunteers
- 500 people
- Sponsor
- Optimata Ltd.
Solid Tumors and Advanced Endometrial Cancer, Endometrial Cancer
A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer
This is a prospective, multi-center, open-label, single-arm, non-randomized, Phase II study to evaluate the efficacy and safety of TKI258 as second-line therapy in patients with either FGFR2 mutated or wild-type advanced and/or…
- Conditions
- Solid Tumors and Advanced Endometrial Cancer, Endometrial Cancer, Second-line Treatment, VEGF
- Trial name
- NCT01379534
- Testing
- TKI258
- Where
- 45 sites in United States, Brazil and 5 more
- Volunteers
- 53 people
- Sponsor
- Novartis Pharmaceuticals
Helicobacter Pylori Infection
Efficacies of Two Bismuth Quadruple Therapies in the Second-line Treatment of H Pylori Infection
From the profiles of antibiotic susceptibility data following eradication therapy, tetracycline, amoxicillin and levofloxacin are all good candidates of antibiotics used in the rescue treatment.
- Trial name
- NCT03779087
- Testing
- 10d TL quadruple therapy, 10d AL quadruple therapy
- Where
- Taiwan
- Volunteers
- 112 people
- Sponsor
- Ping-I (William) Hsu, M.D.
Human Immunodeficiency Virus, HIV
Europe-Africa Research Network for Evaluation of Second-line Therapy
The trial aim is to ascertain what, if anything, needs to be combined with a boosted protease inhibitor (bPI) backbone in second-line therapy in order to maximize the chance of a good clinical outcome following WHO-defined…
- Trial name
- EARNEST (NCT00988039)
- Testing
- Aluvia + 2NRTIs, Aluvia + raltegravir, Aluvia monotherapy
- Where
- 14 sites in Kenya, Malawi and 3 more
- Volunteers
- 1,277 people
- Sponsor
- Justine Boles
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.